Invasive Versus Medical Management in Patients With Chronic Kidney Disease and Non–ST‐Segment–Elevation Myocardial Infarction

Monil Majmundar,Gabriel Ibarra,Ashish Kumar,Rajkumar Doshi,Palak Shah,Roxana Mehran,Grant W. Reed,Rishi Puri,Samir R. Kapadia,Sripal Bangalore,Ankur Kalra

DOI: https://doi.org/10.1161/JAHA.121.025205

2022-06-19

Abstract:Background The role of invasive management compared with medical management in patients with non–ST‐segment–elevation myocardial infarction (NSTEMI) and advanced chronic kidney disease (CKD) is uncertain, given the increased risk of procedural complications in patients with CKD. We aimed to compare clinical outcomes of invasive management with medical management in patients with NSTEMI‐CKD. Methods and Results We identified NSTEMI and CKD stages 3, 4, 5, and end‐stage renal disease admissions using International Classification of Diseases, Tenth Revision, Clinical Modification ( ICD‐10‐CM ) codes from the Nationwide Readmission Database 2016 to 2018. Patients were stratified into invasive and medical management. Primary outcome was mortality (in‐hospital and 6 months after discharge). Secondary outcomes were in‐hospital postprocedural complications (acute kidney injury requiring dialysis, major bleeding) and postdischarge 6‐month safety and major adverse cardiovascular events. Out of 141 052 patients with NSTEMI‐CKD, 85 875 (60.9%) were treated with invasive management, whereas 55 177 (39.1%) patients were managed medically. In propensity‐score matched cohorts, invasive strategy was associated with lower in‐hospital (CKD 3: odds ratio [OR], 0.47 [95% CI, 0.43–0.51]; P <0.001; CKD 4: OR, 0.79 [95% CI, 0.69–0.89]; P <0.001; CKD 5: OR, 0.72 [95% CI, 0.49–1.06]; P =0.096; end‐stage renal disease: OR, 0.51 [95% CI, 0.46–0.56]; P <0.001) and 6‐month mortality. Invasive management was associated with higher in‐hospital postprocedural complications but no difference in postdischarge safety outcomes. Invasive management was associated with a lower hazard of major adverse cardiovascular events at 6 months in all CKD groups compared with medical management. Conclusions Invasive management was associated with lower mortality and major adverse cardiovascular events but minimal increased in‐hospital complications in patients with NSTEMI‐CKD compared with medical management, suggesting patients with NSTEMI‐CKD should be offered invasive management. Nonstandard Abbreviations and Acronyms AKI acute kidney injury CA coronary angiography CAR coronary angiography with revascularization CAWR coronary angiography without revascularization MACE major adverse cardiovascular events NRD Nationwide Readmission Database Clinical Perspective What Is New? In propensity‐score matched analysis of the national database in patients with non–ST‐segment–elevation myocardial infarction and chronic kidney disease (CKD), invasive management was associated with lower mortality, major adverse cardiovascular events, myocardial infarction, and revascularization at 6 months in CKD stages 3 to 5 and end‐stage renal disease. Invasive management was associated with minimal increased risk of in‐hospital acute kidney injury requiring dialysis and major bleeding, but no difference in safety outcomes at 6 months after discharge. Diagnostic angiography was not associated with a higher risk of postprocedure acute kidney injury requiring dialysis compared with medical management. What Are the Clinical Implications? CKD is an independent predictor of morbidity and mortality. Current guidelines acknowledged the lack of evidence on invasive management's beneficial role and safety in patients with non–ST‐segment–elevation myocardial infarction and CKD compared with medical management. Benefits versus risk balance favored invasive management and should be offered to all patients presenting with non–ST‐segment–elevation myocardial infarction and CKD, and the risk of dialysis and major bleeding discussed before revascularization. Chronic kidney disease (CKD) is an independent predictor of cardiovascular morbidity, 1 cardiovascular mortality, 2 and all‐cause mortality. 3 Advanced CKD in patients with non–ST‐segment–elevation myocardial infarction (NSTEMI) is associated with worse morbidity and -Abstract Truncated-